Description

Retatrutide 10mg: The “Triple G” Weight Loss Peptide

Retatrutide is the next-generation “Triple G” agonist currently leading the field of metabolic research. Unlike Semaglutide or Tirzepatide, Retatrutide targets three receptors—GLP-1, GIP, and Glucagon—to deliver unmatched weight loss efficacy.

Why Research Retatrutide?

• Triple-Action Mechanism: Simultaneously stimulates three metabolic pathways for a 3-in-1 approach.

• Unprecedented Results: Clinical data from The New England Journal of Medicine shows weight loss exceeding 24% in 48 weeks.

• Thermogenic Boost: The addition of the Glucagon receptor increases energy expenditure and fat oxidation.

• Metabolic Health: Shown to reduce liver fat by up to 80% in specific research cohorts.

Quick Specifications

• Class: Triple Hormone Receptor Agonist

• Targets: GLP-1, GIP, and Glucagon (GCG)

• Format: 10mg Lyophilized Peptide

• Clinical Status: Phase 3 Research (Estimated 2026 completion)

Performance Comparison

Retatrutide represents the new “ceiling” of weight loss potential. While dual-agonists focus on appetite, Retatrutide adds a metabolic engine through Glucagon receptor activation, promoting a more efficient “metabolic reset.”

Notice: This product is for laboratory research use only. It is not FDA-approved for human consumption.